510(k) Summary

510(k) SPONSOR: Vivorté, Inc.
1044 E. Chestnut Street
Louisville, KY 40204
Contact: Robert Burden
Email: rburden@vivort.com
Telephone: (502) 693-2432
FAX: (502) 714-7235

TRADE NAME: Vivorté BVFTM

COMMON NAME: Calcium phosphate bone void filler; bone void filler

<table>
<thead>
<tr>
<th>Product</th>
<th>Regulation and Description</th>
<th>Product Code</th>
<th>Device Description</th>
<th>Device Class</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vivorté BVFTM</td>
<td>21 CFR 888.3045</td>
<td>MBP</td>
<td>Filler, bone void, osteoinductive (w/o human growth factor)</td>
<td>II</td>
</tr>
<tr>
<td></td>
<td>- Resorbable calcium salt bone void filler device</td>
<td>MQV</td>
<td>Filler, bone void, calcium compound</td>
<td>II</td>
</tr>
</tbody>
</table>

PREDICATE DEVICES: ETEX EquivaBone® Osteoinductive Bone Graft Substitute (K090855)
Synthes® Norian® SRS® Bone Void Filler (K011897)

DEVICE DESCRIPTION:

Vivorté BVFTM is a moldable, self-setting, gradually resorbable, calcium phosphate bone void filler with shaped particles of human bone that contain osteoinductive demineralized bone matrix (DBM). Vivorté BVFTM is indicated for use to fill bony voids or defects of the skeletal system (i.e., extremities, pelvis) that may be surgically created or osseous defects created from traumatic injury to the bone and only for bony voids or defects that are not intrinsic to the stability of the bony structure. Vivorté BVFTM may be manually applied to the bony defect or applied to the defect through a cannula. Vivorté BVFTM isothermically hardens in vivo to form a composite of a carbonated apatite (hydroxyapatite) and shaped particles of human bone that contain DBM. Vivorté BVFTM has a compressive and bending strength that is greater than that of human cancellous bone. The carbonated apatite (hydroxyapatite) which closely resembles the mineral phase of bone provides an osteoconductive scaffold and the shaped particles of human bone contain osteoinductive demineralized bone matrix (DBM). The composite device is gradually
resorbed and remodeled by the body as new bone formation occurs during the healing process. Vivorté BVFTM is provided in various kit sizes corresponding to the amount of bone void filler produced when the components of the kit are mixed together.

Each lot of allograft human bone in the Vivorté BVFTM is assayed for osteoinductive potential using an athymic mouse or rat model. The results of the osteoinductive potential testing may or may not be indicative of the osteoinductivity of Vivorté BVFTM in humans.

**INTENDED USE AND INDICATIONS FOR USE:**

Vivorté BVFTM is a moldable, self-setting, resorbable, calcium phosphate bone void filler with shaped particles of human bone that contain osteotinductive demineralized bone matrix (DBM). Vivorté BVFTM is indicated for use to fill bony voids or defects of the skeletal system (i.e., extremities, pelvis) that may be surgically created or osseous defects created from traumatic injury to the bone and only for bony voids or defects that are not intrinsic to the stability of the bony structure. Vivorté BVFTM may be manually applied to the bony defect or applied to the defect through a cannula. Vivorté BVFTM is resorbed and remodeled by the body as new bone formation occurs during the healing process.

**BASIS FOR SUBSTANTIAL EQUIVALENCE:**

Vivorté BVFTM is chemically and physically substantially equivalent to the ETEX EquivaBone® Osteoinductive Bone Graft Substitute device. Both of these devices are synthetic calcium phosphate based bone void fillers containing osteoinductive demineralized bone matrix. The Vivorté BVFTM and the ETEX EquivaBone® Osteoinductive Bone Graft Substitute devices are both intraoperatively prepared by mixing similar components together to produce self-hardening calcium phosphate bone void fillers that, when implanted in a bony defect, are resorbed and remodeled by the body as new bone formation occurs during the healing process. Both devices have comparable mixing, handling/working, and setting times and, when fully hardened, are composed primarily of apatites that have similar chemical, physical, and mechanical characteristics and properties. The Vivorté BVFTM device and the ETEX EquivaBone® Osteoinductive Bone Graft Substitute device have similar indications for use.

Vivorté BVFTM is also chemically and physically substantially equivalent to the Synthes® Norian® SRS® Bone Void Filler. Both the Vivorté BVFTM and the Synthes® Norian® SRS® Bone Void Filler are composed of synthetic calcium phosphate materials that are virtually identical; however, the Synthes® Norian® SRS® Bone Void Filler does not contain any demineralized bone matrix. Both the Vivorté BVFTM and the Synthes® Norian® SRS® Bone Void Filler devices are intraoperatively prepared by mixing similar components together to produce self-hardening calcium phosphate bone void fillers that, when implanted in a bony defect, are resorbed and remodeled by the body as new bone formation occurs during the healing process. Both devices have comparable mixing, handling/working, and setting times; and both of these devices, when fully hardened, are composed primarily of hydroxyapatite that have similar chemical, physical, and mechanical characteristics and properties. The indications for use of the Vivorté BVFTM and the Synthes® Norian® SRS® Bone Void Filler are similar with the
exception that the Synthes® Norian® SRS® Bone Void Filler does not contain DBM and therefore is not labeled as osteoinductive. The Vivorté BVFTM and the ETEX and Synthes® predicate devices are provided packaged sterile and are intended as prescription use only single use devices.

Non-Clinical Testing

The following testing was performed to demonstrate substantial equivalency of Vivorté BVFTM to the predicate devices.

- Chemical, physical and mechanical testing
- Biocompatibility and toxicity (ISO 10993; ASTM; USP)
- Animal testing

Clinical Testing

Clinical testing was not necessary to determine substantial equivalence between Vivorté BVFTM and the predicate devices.
Dear Dr. Peoples:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820) and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act): 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH’s Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Ronald P. Jean -S for

Mark N. Melkerson
Director
Division of Orthopedic Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure
Indications for Use Statement

510(k) Number: K130703

Device Name: Vivorté BVF™

Indications for Use:

Vivorté BVF™ is a moldable, self-setting, gradually resorbable, calcium phosphate bone void filler with shaped particles of human bone that contain osteoinductive demineralized bone matrix (DBM). Vivorté BVF™ is indicated for use to fill bony voids or defects of the skeletal system (i.e., extremities, pelvis) that may be surgically created or osseous defects created from traumatic injury to the bone and only for bony voids or defects that are not intrinsic to the stability of the bony structure. Vivorté BVF™ may be manually applied to the bony defect or applied to the defect through a cannula. Vivorté BVF™ is gradually resorbed and remodeled by the body as new bone formation occurs during the healing process.

Prescription Use X AND/OR Over-The-Counter Use (Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Laurence D. Coyne -S

(Division Sign-Off)
Division of Orthopedic Devices
510(k) Number: K130703